pomalidomide has been researched along with panobinostat in 3 studies
| Studies (pomalidomide) | Trials (pomalidomide) | Recent Studies (post-2010) (pomalidomide) | Studies (panobinostat) | Trials (panobinostat) | Recent Studies (post-2010) (panobinostat) |
|---|---|---|---|---|---|
| 623 | 121 | 552 | 678 | 95 | 593 |
| Protein | Taxonomy | pomalidomide (IC50) | panobinostat (IC50) |
|---|---|---|---|
| Histone deacetylase 8 | Schistosoma mansoni | 0.45 | |
| Histone deacetylase 3 | Homo sapiens (human) | 0.2031 | |
| Bromodomain-containing protein 4 | Homo sapiens (human) | 0.005 | |
| Cytochrome P450 3A5 | Homo sapiens (human) | 0.0033 | |
| Histone deacetylase 4 | Homo sapiens (human) | 0.3792 | |
| Histone deacetylase 1 | Homo sapiens (human) | 0.181 | |
| Histone deacetylase 7 | Homo sapiens (human) | 0.9434 | |
| Histone deacetylase 2 | Homo sapiens (human) | 0.2527 | |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | 0.007 | |
| Histone deacetylase 11 | Homo sapiens (human) | 0.8396 | |
| Histone deacetylase 8 | Homo sapiens (human) | 0.46 | |
| Histone deacetylase 6 | Homo sapiens (human) | 0.2307 | |
| Histone deacetylase 9 | Homo sapiens (human) | 0.5825 | |
| Histone deacetylase 5 | Homo sapiens (human) | 0.3424 | |
| Histone deacetylase | Plasmodium falciparum (malaria parasite P. falciparum) | 0.0025 | |
| Nuclear receptor corepressor 2 | Homo sapiens (human) | 0.002 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, W; Li, J; Liu, X; Shi, J; Zhang, Z; Zhao, L; Zhou, Y | 1 |
| Orlowski, RZ | 1 |
| Costello, C; Mikhael, JR | 1 |
2 review(s) available for pomalidomide and panobinostat
| Article | Year |
|---|---|
A review on the treatment of multiple myeloma with small molecular agents in the past five years.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Combined Modality Therapy; Deubiquitinating Enzymes; Drug Development; Drug Resistance; Histone Deacetylases; Humans; Ikaros Transcription Factor; Immunomodulating Agents; Models, Molecular; Morpholines; Multiple Myeloma; Phthalimides; Piperidones; Proteasome Inhibitors; Treatment Outcome; Ubiquitin-Protein Ligases | 2022 |
Novel agents for multiple myeloma to overcome resistance in phase III clinical trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunologic Factors; Indoles; Multiple Myeloma; Oligopeptides; Panobinostat; Phosphorylcholine; Piperidines; Proteasome Inhibitors; Pyridines; Remission Induction; Thalidomide; Thiazoles; Treatment Outcome; Vorinostat | 2013 |
1 other study(ies) available for pomalidomide and panobinostat
| Article | Year |
|---|---|
Therapy sequencing strategies in multiple myeloma: who, what and why?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Glycine; Humans; Hydroxamic Acids; Indoles; Multiple Myeloma; Oligopeptides; Panobinostat; Thalidomide | 2018 |